Compare TG Therapeutics Inc (TGTX) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs TotalEnergies SE — how do they compare? TG Therapeutics Inc trades at $54 (market cap $8.26B), while TotalEnergies SE trades at $82.04 (market cap $179.99B). The key difference: TotalEnergies SE is far larger — about 21.8× TG Therapeutics Inc's market cap, and TotalEnergies SE pays a 5.22% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | TTE | |
|---|---|---|
Market Cap | $8.26B | $179.99B |
Sector | Health | Energy |
52-Week High | $59.06 | $93.60 |
52-Week Low | $26.39 | $57.39 |
Enterprise Value | $8.50B | $214.14B |
Dividend Yield | — | 5.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
TotalEnergies (TTE) trades at $83.53, up 2.63% with a bullish technical signal supported by moving averages. The stock shows attractive valuation metrics including a P/E of 11.99 and P/S of 0.96, with strong profitability margins. Recent Q1 2026 earnings beat expectations at $2.45 EPS, while analysts maintain a consensus Buy rating with $100 price target representing 20% upside potential.
TTE presents compelling value with conservative valuation and steady dividend payments, though revenue has declined from $263.3B in 2022 to $182.3B in 2025. Key risks include ongoing Middle East exposure and energy price volatility. The upcoming Q2 earnings report on July 23rd will be crucial for confirming the positive momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
